Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06394817

Beijing Disability Risk and Ageing Monitoring Study

This is a community-based prospective cohort study in Beijing, China. The study has been initialized in 2023 and enrolled older residents. This study aims to develop disability risk assessment standards and an early warning model for older adults.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age Problem Death Disability Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

60 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Xuanwu Hospital, Capital Medical University

Beijing, 100053, China

Location status: Recruiting

Location contact

Yi Tang, M.D., Ph.D.

CONTACT

[email protected]

00861083199456

About this study

This is a community-based prospective cohort study. Individuals who aged 60 years or older, lived in the communities for more than 1 year, and signed the informed consent form were enrolled in the present study. The study has been initialized in 2023 and aimed to develop an early warning model and a series of disability risk assessment methods for older adults. This work consists of three steps as following. First, we will build a community-based cohort and thus set up a database. Second, an intelligence model for disability risk assessment will be developed using the database. Third, a series of procedures will be established according to the risk assessment model.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 60 years or older
  • Lived in the community for more than 1 year
  • Signed the informed consent form

Exclusion criteria

  • Cannot complete the survey

Treatment and study plan

No intervention

Other

No intervention

Primary outcomes

  1. The prevalence and incidence of functional disability using a population-based survey

    Time frame: An average of 1 to 2 years

    Functional disability was measured by Activities of Daily Living, cognitive function (Mini-Mental State Examination) and movement disorder（Short Physical Performance Battery) collected by questionnaires.The minimum value of the Activities of Daily Living is 0, and the maximum value is 100, the higher the score, the better the outcome.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.

  2. The prevalence and incidence of mild cognitive impairment using a population-based survey

    Time frame: An average of 1 to 2 years

    Mild cognitive impairment was measured using Mini-Mental State Examination collected by questionnaire.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.

  3. The prevalence and incidence of dementia using a population-based survey

    Time frame: An average of 1 to 2 years

    Dementia was determined by diagnosis of hospitalization or diagnosis of death or Clinical Dementia Rating scale. The minimum value of the Clinical Dementia Rating is 0, and the maximum value is 3, the higher the score, the worse the outcome.

  4. The conversion rate of normal to mild cognitive impairment

    Time frame: An average of 1 to 2 years

    Percentage of enrolled population that convert from normal to mild cognitive impairment

  5. The conversion rate of mild cognitive impairment to dementia

    Time frame: An average of 1 to 2 years

    Percentage of enrolled population that convert from mild cognitive impairment to dementia

  6. The genetic and environmental factors for mild cognitive impairment and dementia at genomic and expression levels

    Time frame: An average of 1 to 2 years

    Discover risk factors including genetic susceptibility loci (APOE genes and other risk genes) using gene sequencing, cardiovascular risk factors (blood glucose, cholesterol, homocysteine) using laboratory tests, and unhealthy lifestyle using questionnaire.

  7. The biomarkers for normal, mild cognitive impairment, and dementia diagnosis

    Time frame: An average of 1 to 2 years

    Humoral biomarkers are included Aβ42, Aβ40, phosphated tau and total tau in plasma, cerebrospinal fluid, saliva, and urine. Imaging biomarkers are included cerebral volume, glucose metabolism, amyloid and tau deposition of whole brain or hippocampus.

  8. The prevalence and incidence of movement disorder using a population-based survey

    Time frame: An average of 1 to 2 years

    Movement disorder was measured using Short Physical Performance Battery collected by questionnaire.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.

Study contacts

Contact information is provided by the study sponsor or research team.

Yi Tang, MD., PhD

CONTACT

[email protected]

00861083199456

Sponsors and collaborators

Lead sponsor

Xuanwu Hospital, Beijing

Other

Registry information

Acronym: BEAM

Important dates

Study start
2023
Primary completion
2063
Study completion
2063
First posted
May 1, 2024
Registry last updated
Jun 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.